Related Experiment Video
Updated: Jul 31, 2026
09:11
Visualizing Dengue Virus through Alexa Fluor Labeling
Published on: July 9, 2011
14.4K
Riboflavin and ultraviolet light: impact on dengue virus infectivity
H M Faddy1,2, J J Fryk3, D Watterson4
1Research and Development, Australian Red Cross Blood Service, Brisbane, Qld, Australia. hfaddy@redcrossblood.org.au.
Vox Sanguinis
|June 10, 2016
Summary
Riboflavin and UV light treatment modestly reduced Dengue virus (DENV 1-4) infectivity in platelet concentrates. This pathogen inactivation method shows potential for enhancing transfusion safety against emerging DENV threats.
Area of Science:
- Transfusion Medicine
- Virology
- Blood Safety
Background:
- Dengue viruses (DENV 1-4) are emerging globally, posing a significant risk to transfusion safety.
- Pathogen inactivation is being explored as a strategy to mitigate DENV transfusion transmission risks.
Purpose of the Study:
- To evaluate the efficacy of riboflavin and UV light in inactivating DENV serotypes 1-4 within platelet concentrates.
Main Methods:
- Dengue viruses (DENV 1-4) were added to platelet concentrates.
- Samples were treated using a combination of riboflavin and UV light.
- Viral infectivity was quantified before and after treatment to determine log reduction.
Main Results:
- All four DENV serotypes showed modest reductions in infectivity after treatment.
- DENV-4 exhibited the greatest reduction (1.81 log), followed by DENV-3 (1.71 log), DENV-2 (1.45 log), and DENV-1 (1.28 log).
Conclusions:
- Riboflavin and UV light treatment leads to a modest reduction in DENV 1-4 titers in platelet concentrates.
- Given the rise in DENV transfusion-transmitted cases, further strategies are needed to ensure blood safety.
